14717-97-6 Usage
Uses
Used in Pharmaceutical Research:
DL-4-Thiazolylalanine is used as a research compound for its potential therapeutic properties, particularly in the treatment of neurodegenerative diseases and cancer. Its unique structure allows it to interact with biological systems in ways that are distinct from proteinogenic amino acids.
Used in Biochemical Research:
In biochemical applications, DL-4-Thiazolylalanine serves as a tool to study the effects of non-proteinogenic amino acids on various biological processes. Its metal-chelating ability is of particular interest, offering insights into metal ion interactions within biological systems.
Used in Drug Development:
DL-4-Thiazolylalanine is utilized as a lead compound in drug development, given its potential to be modified and optimized for specific therapeutic targets. Its metal-chelating properties may be harnessed to create drugs that can target metal-dependent enzymes or disrupt metal ion homeostasis in disease processes.
Used in Chemical Synthesis:
DL-4-Thiazolylalanine is employed as a building block in the synthesis of complex organic compounds and pharmaceuticals, taking advantage of its reactive thiazole ring for the formation of diverse chemical entities with potential applications in medicine and other fields.
Check Digit Verification of cas no
The CAS Registry Mumber 14717-97-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,7,1 and 7 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 14717-97:
(7*1)+(6*4)+(5*7)+(4*1)+(3*7)+(2*9)+(1*7)=116
116 % 10 = 6
So 14717-97-6 is a valid CAS Registry Number.
InChI:InChI=1/C6H8N2O2S/c7-5(6(9)10)1-4-2-11-3-8-4/h2-3,5H,1,7H2,(H,9,10)
14717-97-6Relevant academic research and scientific papers
Substituted quinoxaline-2-ones as glutamate receptor antagonists
-
, (2008/06/13)
A novel series of substituted quinoxaline 2-ones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate receptor antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer's, Parkinson's, and Huntington's Diseases.
